Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.53
-$0.11(-0.75%)
At close: 4:00 PM EDT
$14.53
-$0.11(-0.75%)
Day’s Range― - ―
52-Week Range$1.31 - $19.40
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.36M
Market Cap
$66.61M
Enterprise Value$622.17
Total Cash (Recent Filing)$117.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 18, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding37,423,916
10 Day Avg. Volume1,158,957
30 Day Avg. Volume1,364,040
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside-38.06% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetMinimal debt reduces refinancing pressure and preserves financial flexibility while the company advances its pipeline. The larger equity base provides a stronger platform than a highly levered structure, although continued losses could erode it.
Long-term Supply And Licensing StabilitySecured manufacturing and extended licensing terms reduce operational uncertainty for oral levosimendan development. The agreement supports continuity, scale-up planning and regulatory flexibility if the program is refocused.
Exploratory Efficacy Signals In Severe DiseaseBiomarker and subgroup findings suggest the lead therapy may have greater value in patients with heavier disease burden. These signals could support a targeted registrational strategy, though they require regulatory validation and further evidence.
Bears Say
Phase 3 Trial Failed Primary EndpointFailure of the pivotal trial weakens the immediate regulatory case for TNX-103 and increases development uncertainty. A redesigned or narrower strategy may require additional time, capital and clinical evidence before commercialization.
Pre-revenue Model With Widening LossesThe absence of revenue means TENX has no operating earnings base to fund research or corporate costs. Persistent and expanding losses indicate a long path to profitability and leave results highly dependent on clinical execution.
Accelerating Cash Burn And Funding DependenceDeepening negative cash flow reduces the time available to advance programs without new financing. External funding may dilute shareholders or constrain development if capital becomes difficult to obtain, especially after the trial miss.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $1.31 and its highest was $19.40 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $66.61M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.381 by $0.031.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Overvalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 37,423,916 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.381. Following the earnings report the stock price went down -9.272%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (-38.06% Downside)
$9.00 (-38.06% Downside)
Blogger Sentiment
Neutral
TENX Sentiment 55%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 459.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.93%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$9.00
▼(-38.06% Downside)
Technical Analysis
Enanta Pharmaceuticals
―
Arcturus Therapeutics
―
ProQR
―
Corbus Pharmaceuticals
―
Atea Pharmaceuticals
―
Ownership Overview
0.11% Insiders
8.54% Mutual Funds
35.91% Other Institutional Investors
47.49% Public Companies and
Individual Investors